These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 34503126)

  • 1. Comprehensively Exploring the Mutational Landscape and Patterns of Genomic Evolution in Hypermutated Cancers.
    Lin PC; Yeh YM; Hsu HP; Chan RH; Lin BW; Chen PC; Pan CC; Hsu KF; Hsiao JR; Shan YS; Shen MR
    Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and mutational determinants of high tumor mutation burden in breast cancer.
    Barroso-Sousa R; Jain E; Cohen O; Kim D; Buendia-Buendia J; Winer E; Lin N; Tolaney SM; Wagle N
    Ann Oncol; 2020 Mar; 31(3):387-394. PubMed ID: 32067680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures.
    Johnson A; Severson E; Gay L; Vergilio JA; Elvin J; Suh J; Daniel S; Covert M; Frampton GM; Hsu S; Lesser GJ; Stogner-Underwood K; Mott RT; Rush SZ; Stanke JJ; Dahiya S; Sun J; Reddy P; Chalmers ZR; Erlich R; Chudnovsky Y; Fabrizio D; Schrock AB; Ali S; Miller V; Stephens PJ; Ross J; Crawford JR; Ramkissoon SH
    Oncologist; 2017 Dec; 22(12):1478-1490. PubMed ID: 28912153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutational Analysis Identifies Therapeutic Biomarkers in Inflammatory Bowel Disease-Associated Colorectal Cancers.
    Din S; Wong K; Mueller MF; Oniscu A; Hewinson J; Black CJ; Miller ML; Jiménez-Sánchez A; Rabbie R; Rashid M; Satsangi J; Adams DJ; Arends MJ
    Clin Cancer Res; 2018 Oct; 24(20):5133-5142. PubMed ID: 29950348
    [No Abstract]   [Full Text] [Related]  

  • 5. Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine.
    Nebot-Bral L; Brandao D; Verlingue L; Rouleau E; Caron O; Despras E; El-Dakdouki Y; Champiat S; Aoufouchi S; Leary A; Marabelle A; Malka D; Chaput N; Kannouche PL
    Eur J Cancer; 2017 Oct; 84():290-303. PubMed ID: 28846956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. APOBEC mutagenesis is tightly linked to the immune landscape and immunotherapy biomarkers in head and neck squamous cell carcinoma.
    Faden DL; Ding F; Lin Y; Zhai S; Kuo F; Chan TA; Morris LG; Ferris RL
    Oral Oncol; 2019 Sep; 96():140-147. PubMed ID: 31422205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy of DNA mismatch repair enzyme immunohistochemistry as a screening test for hypermutated gliomas.
    McCord M; Steffens A; Javier R; Kam KL; McCortney K; Horbinski C
    Acta Neuropathol Commun; 2020 Feb; 8(1):15. PubMed ID: 32051040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of Pan-Cancer Patients With Ultrahigh Tumor Mutation Burden.
    Yuan H; Ji J; Shi M; Shi Y; Liu J; Wu J; Yang C; Xi W; Li Q; Zhu W; Li J; Gong X; Zhang J
    Front Oncol; 2021; 11():682017. PubMed ID: 33968789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate Cancer.
    Ritch E; Fu SYF; Herberts C; Wang G; Warner EW; Schönlau E; Taavitsainen S; Murtha AJ; Vandekerkhove G; Beja K; Loktionova Y; Khalaf D; Fazli L; Kushnir I; Ferrario C; Hotte S; Annala M; Chi KN; Wyatt AW
    Clin Cancer Res; 2020 Mar; 26(5):1114-1125. PubMed ID: 31744831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential and co-occurring DNA damage response genetic mutations impact survival in stage III colorectal cancer patients receiving adjuvant oxaliplatin-based chemotherapy.
    Lin PC; Yeh YM; Chan RH; Lin BW; Chen PC; Pan CC; Shen MR
    BMC Cancer; 2021 Mar; 21(1):217. PubMed ID: 33653301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypermutation as a potential predictive biomarker of immunotherapy efficacy in high-grade gliomas: a broken dream?
    Gatto L; Franceschi E; Tosoni A; Nunno VD; Bartolini S; Brandes AA
    Immunotherapy; 2022 Jul; 14(10):799-813. PubMed ID: 35670093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial Cancer.
    Natesan D; Zhang L; Martell HJ; Jindal T; Devine P; Stohr B; Espinosa-Mendez C; Grenert J; Van Ziffle J; Joseph N; Umetsu S; Onodera C; Turski M; Chan E; Desai A; Aggarwal R; Wong A; Porten S; Chou J; Friedlander T; Fong L; Small EJ; Sweet-Cordero A; Koshkin VS
    Front Oncol; 2022; 12():816706. PubMed ID: 35321431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and genomic characterization of mutational signatures across human cancers.
    Liao J; Bai J; Pan T; Zou H; Gao Y; Guo J; Xu Q; Xu J; Li Y; Li X
    Int J Cancer; 2023 Apr; 152(8):1613-1629. PubMed ID: 36533638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression.
    Ashley CW; Da Cruz Paula A; Kumar R; Mandelker D; Pei X; Riaz N; Reis-Filho JS; Weigelt B
    Gynecol Oncol; 2019 Jan; 152(1):11-19. PubMed ID: 30415991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel 4-gene prognostic signature for hypermutated colorectal cancer.
    Ge W; Cai W; Bai R; Hu W; Wu D; Zheng S; Hu H
    Cancer Manag Res; 2019; 11():1985-1996. PubMed ID: 30881123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The somatic POLE P286R mutation defines a unique subclass of colorectal cancer featuring hypermutation, representing a potential genomic biomarker for immunotherapy.
    Ahn SM; Ansari AA; Kim J; Kim D; Chun SM; Kim J; Kim TW; Park I; Yu CS; Jang SJ
    Oncotarget; 2016 Oct; 7(42):68638-68649. PubMed ID: 27612425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic characterization of metastatic ultra-hypermutated interdigitating dendritic cell sarcoma through rapid research autopsy.
    Chen HZ; Bonneville R; Yu L; Wing MR; Reeser JW; Krook MA; Miya J; Samorodnitsky E; Smith A; Martin D; Dao T; Guo Q; Liebner D; Freud AG; Allenby P; Roychowdhury S
    Oncotarget; 2019 Jan; 10(3):277-288. PubMed ID: 30719225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypermutation and microsatellite instability in gastrointestinal cancers.
    Yuza K; Nagahashi M; Watanabe S; Takabe K; Wakai T
    Oncotarget; 2017 Dec; 8(67):112103-112115. PubMed ID: 29340115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatic Genomics and Clinical Features of Lung Adenocarcinoma: A Retrospective Study.
    Shi J; Hua X; Zhu B; Ravichandran S; Wang M; Nguyen C; Brodie SA; Palleschi A; Alloisio M; Pariscenti G; Jones K; Zhou W; Bouk AJ; Boland J; Hicks B; Risch A; Bennett H; Luke BT; Song L; Duan J; Liu P; Kohno T; Chen Q; Meerzaman D; Marconett C; Laird-Offringa I; Mills I; Caporaso NE; Gail MH; Pesatori AC; Consonni D; Bertazzi PA; Chanock SJ; Landi MT
    PLoS Med; 2016 Dec; 13(12):e1002162. PubMed ID: 27923066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy.
    Goh G; Walradt T; Markarov V; Blom A; Riaz N; Doumani R; Stafstrom K; Moshiri A; Yelistratova L; Levinsohn J; Chan TA; Nghiem P; Lifton RP; Choi J
    Oncotarget; 2016 Jan; 7(3):3403-15. PubMed ID: 26655088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.